Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD | Market Cap | 17.35M -72.9% |
| Revenue (ttm) | 12.87M -1.1% |
| Net Income | -56.95M |
| EPS | -0.02 |
| Shares Out | 4.34B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,184,407 |
| Open | 0.0040 |
| Previous Close | 0.0040 |
| Day's Range | 0.0030 - 0.0040 |
| 52-Week Range | 0.0030 - 0.0370 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 26, 2026 |
About Radiopharm Theranostics
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also... [Read more]
Financial Performance
In fiscal year 2026, Radiopharm Theranostics's revenue was 12.87 million, a decrease of -1.05% compared to the previous year's 13.00 million. Losses were -56.95 million, 48.5% more than in 2025.
Financial StatementsNews
Radiopharm Theranostics Limited - Depositary Receipt Price Target Increased by 10.97% to $14.67
The average one-year price target for Radiopharm Theranostics Limited - Depositary Receipt (NASDAQCM:RADX) has been revised to $14.67 / share. This is an increase of 10.97% from the prior estimate of ...
Radiopharm Theranostics aligns with FDA on single Phase 3 trial for RAD101
Radiopharm (RADX) Theranostics announced receipt of the final meeting minutes following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, at which Radiopharm reached alignment wit...
Radiopharm Theranostics aligns with FDA on single Phase 3 trial for RAD101
Radiopharm (RADX) Theranostics announced receipt of the final meeting minutes following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, at which Radiopharm reached alignment wit...
Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases
Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds
Radiopharm Aligns With FDA On Single Pivotal Phase 3 RAD101 Trial For Brain Metastases
(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Wednesday it received the final minutes of its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, confirming agreement on the desig...
Radiopharm Theranostics Reports Business Update
Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration
Radiopharm Theranostics Earnings release: Q1 2027
Radiopharm Theranostics released its Q1 2027 earnings on October 29, 2026, summarizing the period's financial results.
Radiopharm completes EOP2 meeting with FDA for RAD101
Radiopharm (RADX) announced the completion of an End-of-Phase 2, or EOP2, meeting with the FDA regarding RAD101, the company’s investigational radiopharmaceutical imaging agent for the detection of br...
Radiopharm Theranostics Annual report: H2 2026
Radiopharm Theranostics has published its H2 2026 annual report on September 29, 2026.
Radiopharm Theranostics Registration statement: Registration filing
Radiopharm Theranostics filed a registration statement on September 14, 2026, providing details about a securities offering with the SEC.
Radiopharm announces data from imaging trial of RAD 301
Radiopharm (RADX) announced data from the Phase 1 imaging trial designed to evaluate the safety, biodistribution and dosimetry of RAD 301 in healthy volunteers and subjects with Pancreatic Ductal Aden...
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting pote...
Radiopharm doses first patient in second cohort of RV-01 trial
Radiopharm (RADX) announced that it has dosed the first patient in the second cohort of its first-in-human Phase 1/2a clinical trial of RV-01 in patients with B7-H3 expressing tumors. This…
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01, ...
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated cl...
Radiopharm schedules End-of-Phase 2 meeting with FDA for RAD101
Radiopharm (RADX) announced that it has scheduled an End-of-Phase 2 meeting with the FDA for October 1, to align on the design of a pivotal Phase 3 trial to evaluate…
Radiopharm announces $4.1M registered direct offering
Radiopharm (RADX) announced that it has entered into a securities purchase agreement, or SPA, with certain U.S. accredited institutional investors to issue, in a registered direct offering, 1.282M Ame...
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on de...
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminar...
Radiopharm Theranostics trading halted, news pending
19:56 EDT Radiopharm (RADX) Theranostics trading halted, news pending
Radiopharm initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Radiopharm (RADX) with a Buy rating and $6 price target The company seeks to expand the cancer patient populations that may benefit from targeted radiotherapy,…
Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference
A differentiated radiopharmaceutical pipeline is advancing four clinical programs in parallel, with near-term catalysts expected from ongoing phase I and II trials. Imaging agent RAD 101 is nearing phase III and potential commercialization, while operational efficiency and strategic partnerships support growth.
Radiopharm Theranostics Slides: Deutsche Bank ADR Virtual Investor Conference
Radiopharm Theranostics has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Radiopharm Theranostics Earnings release: Q3 2026
Radiopharm Theranostics released its Q3 2026 earnings on April 22, 2026, summarizing the period's financial results.